Showing 11 posts of 11 posts found.

MorphoSys shares phase 3 trial results for pelabresib in myelofibrosis treatment

November 23, 2023
Research and Development Haematology, clinical trial, morphosys, myelofibrosis, pelabresib

MorphoSys has announced topline results from its phase 3 MANIFEST-2 study, which assessed pelabresib, an investigational BET inhibitor, in combination …


FDA gives nod for Monjuvi combo for second-line relapsed or refractory diffuse large B-cell lymphoma

August 3, 2020
Sales and Marketing FDA, Incyte, Monjuvi, morphosys, pharma

The FDA has awarded MorphoSys and Incyte US approval for their Fc-modified cytolytic CD19-targeting monoclonal antibody Monjuvi (tafasitamab-cxix), when used …


MorphoSys and Incyte forge potential $1.1bn partnership to develop B cell malignancy drug candidate

January 14, 2020
Manufacturing and Production, Sales and Marketing Incyte, morphosys, pharma, tafasitamab

MorphoSys and Incyte have joined together in a partnership to develop and commercialise the latter’s anti-CD19 antibody tafasitamab as a …


Working Life Interview: Jean-Paul Kress, CEO of MorphoSys

January 13, 2020
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Working Life, feature, morphosys, pharma

With a medical doctorate as well as degrees in pharmacology and immunology under your belt, was your path always to …


Morphosys, Novartis and Galaagos shut down development of atopic dermatitis candidate

October 31, 2019
Research and Development Galapagos, Novartis, atopic dermatitis, morphosys, pharma

The trio of Galapagos, MorphoSys and Novartis Pharma has revealed that all further development of its MOR106 drug candidate for …


Novartis muscular drug fails in Phase III trials

April 22, 2016
Medical Communications, Research and Development FDA, Novartis, bimagrumab, breakthrough, morphosys, muscular, phase III

A muscular drug developed by Novartis (NYSE: NVS), in partnership with MorphoSys (ETR: MOR), failed to meet its primary endpoint …


Janssen and Genmab sued for patent infringement in US

April 5, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Genmab, Janssen, darzalex, morphosys, patent infringement

German biotech company, Morphosys, is suing Janssen and Genmab for alleged patent infringement in their oncology drug, Darzalex (daratumumab).

Red blood cells

ASH 2015 roundup: Amgen, MorphoSys, Novartis and Roche present new trial data

December 8, 2015
Research and Development Amgen, Cancer, Novartis, Roche, ash, morphosys, oncology

Amgen Amgen presented data from three Phase II trials evaluating Blincyto (blinatumomab) in acute lymphoblastic leukemia (ALL)- a rare and …

GSK image

GSK licences RA drug

June 5, 2013
Research and Development, Sales and Marketing GSK, RA, morphosys

GlaxoSmithKline is gambling millions of euros on an investigational drug in a bid to get an edge in the fight …

Pharma manufacturing news in brief

March 22, 2011
Manufacturing and Production American Regent, Berkshire Hathaway, Cytovance, Intercell, Solagran, West Pharmaceutical Services, morphosys, pharma contract manufacturing

Lubrizol bought for $9.7 billion by Berkshire Hathaway, plus the latest pharma manufacturing and quality news. Berkshire Hathaway, run by …


Dr Lisa Rojkjaer, head of clinical development, MorphoSys

October 15, 2009
Research and Development appointment, morphosys, research and development

MorphoSys has appointed Dr Lisa Rojkjaer as vice president and head of clinical development. Dr Rojkjaer joins MorphoSys from Novartis …

Latest content